Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting RET alterations in non-small cell lung cancer.

Current problems in cancer - 1 Apr 2024

Nishikawa Go, Klein Mark A

Abstract excerpt

Rearranged during transfection (RET) alterations, which lead to aberrant activation of the RET proto-oncogene, have been identified in various cancers. In non-small cell lung cancer (NSCLC), RET mutations often manifest as RET fusion genes and are observed in 1-2 % of patients with NSCLC. In recent years, selective RET inhibitors such as selpercatinib and pralsetinib, approved by the Food and Drug Administration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-ret

Source

Identifiers

PMID: 38494387
DOI: 10.1016/j.currproblcancer.2024.101074

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting RET alterations in non-small cell lung cancer.PMID 38494387Read ↗

Treatment of non–small cell lung cancer with RET rearrangementsSemantic proximity Read ↗

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read ↗

Therapeutic strategies in RET gene rearranged non-small cell lung cancerSemantic proximity Read ↗

[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.Semantic proximity Read ↗

Current management of RET rearranged non-small cell lung cancerSemantic proximity Read ↗

Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.Semantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

RET-rearranged non-small-cell lung cancer and therapeutic implications.Semantic proximity Read ↗

RET signaling pathway and RET inhibitors in human cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.